ArticleFrontiers in aging neuroscience2026
Impact of Lewy body and limbic-predominant TDP-43 neuropathology on cognitive and neuropsychiatric trajectory in Alzheimer's disease: a retrospective neuropathological study.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alzheimer's disease (AD) is the leading cause of neurodegenerative dementia, and mixed neuropathological changes including Lewy body (LB-NC) and TDP-43 (LATE-NC) are commonly observed in patients with AD. We examined the baseline cross-sectional and longitudinal effects of these co-pathologies on cognitive and neuropsychiatric trajectories. Methods: We investigated 77 participants who had available autopsy data and showed intermediate to high levels of AD neuropathological change from the ADNI database. Participants were categorized based on the presence or absence of LB-NC or LATE-NC. The impact of LB-NC and LATE-NC on baseline and longitudinal clinical features was assessed using linear regression and linear mixed-effects models, respectively. Results: Thirty-eight (49.4%) had LB-NC, and 39 (50.6%) had LATE-NC. At baseline, the presence of LB-NC was not associated with cognitive function or neuropsychiatric symptoms, whereas the presence of LATE-NC was associated with better trail-making test performance and less severe sleep disturbance. Longitudinally, the presence of LB-NC was associated with faster cognitive decline in global cognitive function, memory, language, and executive function, whereas the presence of LATE-NC was associated with a slower decline in language function. Neither LB-NC nor LATE-NC influenced the longitudinal trajectory of neuropsychiatric symptoms. Conclusion: Among patients with pathologically confirmed AD, the presence of LB-NC accelerated cognitive decline, whereas the presence of LATE-NC was not associated with overall cognitive trajectories. Investigating comorbid pathologies is essential for prognostic stratification and the development of personalized therapeutic strategies in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.